Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca diabetes drug shows heart failure promise

AstraZeneca made strides toward the company’s goal of adding heart failure to the conditions that can be treated by Farxiga, putting the diabetes drug ahead of a rival medicine from Eli Lilly.

Read More »

Novo Nordisk’s new diabetes, obesity drugs lift sales outlook

Novo Nordisk’s sales forecast for 2019 was raised due to growing demand for obesity products and a new injectable treatment for diabetes, which is now the company’s growth engine as insulin sales decline.

Read More »

Diabetes Treatments Continue to Advance With New Data from Merck and Novo Nordisk

Novo Nordisk presented data from three separate studies that highlighted the efficacy of oral semaglutide, an investigational once-daily glucagon-like peptide-1 (GLP-1) analog in a pill. Additionally, data showed the efficacy of Merck’s Januvia on type 2 diabetes patients age 65 and older in comparison to the SGLT2 inhibitor dapagliflozin.

Read More »

Novo Nordisk Q1 2019 profit tops forecast

Danish drugmaker Novo Nordisk beat first-quarter 2019 operating profit forecasts, helped by higher sales of the company’s biggest new drug hope, a treatment for type 2 diabetes.

Read More »

PhaseBio Receives FDA Breakthrough Therapy Designation and Licenses GLP-1 Analog to ImmunoForge

PhaseBio Pharmaceuticals’ antiplatelet drug PB2452 received Breakthrough Therapy designation from the U.S. FDA.

Read More »

Novo Nordisk submits diabetes pill for U.S. approval

Novo Nordisk submitted the company’s oral semaglutide drug, a pill that management hopes will transform the diabetes market, for approval in the United States.

Read More »

Novo Nordisk’s new diabetes drug, outlook lift shares

Novo Nordisk reported solid growth for the company’s new diabetes drug and will submit a tablet version – a key growth hope – for U.S. approval in first-quarter 2019, lifting the Danish drugmaker’s shares.

Read More »

Lilly’s Trulicity reduces heart risks in clinical study

Eli Lilly.’s top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes in a large clinical trial.

Read More »

Lilly’s two-in-one diabetes product data impresses

Eli Lilly’s new two-in-one diabetes drug was successful in lowering blood sugar and reducing weight, sending the company’s shares to a record high and weighing on those of arch-rival Novo Nordisk.

Read More »

Lilly Licenses Chugai Pharma’s Oral Diabetes Drug for $50 Million Upfront

Eli Lilly signed a licensing deal for Chugai Pharmaceutical’s oral non-peptidic GLP-1 receptor agonist OWL833.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom